285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors

by Marcus Butler, David Hong, Ryan Sullivan, Matthew Frigault, Sarah Boross-Harmer, Ecaterina Dumbrava, Jean-Marc Navenot, Svetlana Fayngerts, Jane Bai, Elliot Norry, Paula Fracasso, Russell Pachynski, Partow Kebriaei, Amy Sauer, Francine Brophy
Published 2020-11-01

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

by David S. Hong, Marcus O. Butler, Russell K. Pachynski, Ryan Sullivan, Partow Kebriaei, Sarah Boross-Harmer, Armin Ghobadi, Matthew J. Frigault, Ecaterina E. Dumbrava, Amy Sauer, Francine Brophy, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry G. Batrakou, Ruoxi Wang, Luisa M. Solis, Dzifa Yawa Duose, Joseph P. Sanderson, Andrew B. Gerry, Diane Marks, Jane Bai, Elliot Norry, Paula M. Fracasso
Published 2022-03-01

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients

by Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, Cynthia Kurtis, Mark Carroll, Marian Van Kerckhoven, Sofie Van Rossom, Kelly Schats, Konstantinos Avraam, Robyn Broad, Karen Howe, Ashley Liddle, Amber Clayton, Ruoxi Wang, Laura Quinn, Joseph P. Sanderson, Cheryl McAlpine, Carly Carozza, Eric Pimpinella, Susan Hsu, Francine Brophy, Erica Elefant, Paige Bayer, Dennis Williams, Marcus O. Butler, Jeffrey M. Clarke, Justin F. Gainor, Ramaswamy Govindan, Victor Moreno, Melissa Johnson, Janet Tu, David S. Hong, George R. Blumenschein, Jr.
Published 2024-06-01